Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

Antwerp University Hospital, Edegem

Centre Antoine Lacassagne, Nice

National Taiwan University Hospital, Taipei

Weill Cornell Medical College-New York Presbyterian Hospital, New York

Taipei Veterans General Hospital, Taipei

Helios Klinikum Emil von Behring GmbH, Berlin

Georgetown University Medical Center, Washington D.C.

IEO, Milan

Asst Grande Ospedale Metropolitano Niguarda, Milan

Pius-Hospital, Oldenburg

Hospital Ramon y Cajal, Madrid

Hospital Universitario 12 de Octubre, Madrid

Hôpital Larrey, Toulouse

Mayo Clinic-Jacksonville, Jacksonville

Institut Bergonie, Bordeaux

CHU de Rennes - Hopital de Pontchaillo, Rennes

Universitätsklinikum Essen, Essen

Ospedale Santa Maria Delle Croci, Ravenna

Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez, Lille

Centre Léon Bérard, Lyon

Thoraxklinik Heidelberg gGmbH, Heidelberg

Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas

Institut Curie, Paris

University of Colorado Anschutz Medical Campus, Aurora

Klinikum der Universität München, München

Mayo Clinic Hospital, Phoenix

UC Irvine Medical Center, Orange

Gustave Roussy, Villejuif

Oregon Health & Science University, Portland

Seattle Cancer Care Alliance, Seattle

Beijing Cancer Hospital, Beijing

Beijing Cancer Hospital, Beijing

The Chinese University of Hong Kong, Shatin

National Cancer Centre, Singapore

Fudan University Shanghai Cancer Center, Shanghai

Fudan University Shanghai Cancer Center, Shanghai

Jinan Central Hospital, Jinan

Tianjin Medical University Cancer Institute & Hospital, Tianjing

Zhejiang Cancer Hospital, Hangzhou

First Affiliated Hospital of Gannan Medical University, Ganzhou

Fujian Provincial Cancer Hospital, Fuzhou

Chongqing Cancer Hospital, Chongqing

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

Henan Cancer Hospital, Zhengzhou

Sun Yet-sen University Cancer Center, Guangzhou

Guangdong General Hospital, Guangzhou

The affiliated Cancer Hospital, School of Medicine, UESTC, Chengdu

West China Hospital, Sichuan University, Chengdu

Gansu Cancer Hospital, Lanzhou

Sylvester Comprehensive Cancer Center, Miami

Maryland Oncology Hematology, P.A., Columbia

Massachusetts General Hospital., Boston

University of Michigan, Ann Arbor

Mayo Clinic Rochester, Rochester

Washington University School of Medicine in St. Louis, St Louis

Albany Medical Center, Albany

Texas Oncology-Austin Midtown, Austin

The University of Texas MD Anderson Cancer Center, Houston

Istituto Nazionale Tumori Regina Elena, Rome

Antoni van Leeuwenhoek Ziekenhuis, Amsterdam

Universitair Medisch Centrum Groningen, Groningen

Seoul National University Hospital, Seoul

Asan Medical Center, Seoul

Samsung Medical Center, Seoul

Severance Hospital, Yonsei University Health System, Seoul

Institut Catala d Oncologia Hospitalet, L'Hospitalet de Llobregat

Vall d?Hebron Institute of Oncology (VHIO), Barcelona, Barcelona

Hospital Clinic de Barcelona, Barcelona

Guys and St Thomas NHS Foundation Trust, Guys Hospital, London

University College London Hospitals NHS Foundation Trust, London

The Christie NHS Foundation Trust, Manchester